conduits to be used effectively for long periods when the underlying stenosis is corrected or bypass grafted. 5, 8, 11, [19] [20] [21] [22] None of the earlier published studies compared the results of thrombolysis/PTA with the results of thrombectomy/open patch repair for failed above-knee PTFE grafts. This report evaluates the results of both modalities in a 10-year period.
METHODS
Patients with failed (thrombosed, first failure) aboveknee femoropopliteal bypass grafts (PTFE, Goretex, W.L. Gore, Flagstaff, Ariz) during a 10-year period (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) were given the option to choose between surgical thrombectomy/open patch repair for localized anastomotic short stenoses (a lesion of ≤2 cm; group A, 31 patients) and thrombolysis/PTA or thrombectomy/balloon angioplasty, when thrombolysis failed or was contraindicated (group B, 26 patients). During this 10-year period, 309 above-knee PTFE femoropopliteal bypass grafts were done, and 96 patients had thrombosed or failed PTFE grafts (first time failure). Thirty-one of these patients were treated with other modalities (eg, thrombectomy or lysis only, new bypass grafts for below-knee popliteal or distal vessels [with autogenous vein]). Eight other patients were treated conservatively (anticoagulation) for several reasons, such as being at high-risk and having stable limbs or because they refused further intervention. The indications for the initial surgery were similar in patients in whom failed bypass grafts developed and patients whose bypass grafts did not fail: disabling claudication with failed medical therapy in 56% of patients in whom failed grafts did not develop versus 55% in patients with failed grafts. The remaining indications were for rest pain, trophic changes, or both. The preoperative evaluation included a clinical vascular examination, duplex ultrasound scanning, measurement of the ankle brachial index, and arteriography visualizing the abdominal aorta and arteries of both lower extremities. All demographic and clinical characteristics were collected and analyzed.
The degree of acute ischemia was categorized according to the criteria suggested by the Ad Hoc Committee on the Reporting Standards of the Society for Vascular Surgery and the International Society of Cardiovascular Surgery (SVS/ISCVS). 19, 20 Only patients with acute ischemia (≤14 days) were included. All patients with inflow or outflow disease were excluded from this study, including patients with proximal aortoiliac occlusive disease that necessitated an intervention or popliteal artery disease that was not localized to 1 to 2 cm from the distal suture line (eg, mid/distal popliteal artery or poor below-knee runoff [absence of ≥2-vessel runoff] which necessitated a distal below-knee bypass grafting procedure or other reconstruction).
Surgical thrombectomy/patch angioplasty. Surgical procedures were performed in an operating room equipped with a digital fluoroscopy unit. A Fluoroplus (Phillips Medical System) was used during the first half of the study, and a special vascular suite equipped with the International Surgical System (Phoenix, Ariz) was used in the second half of the study. Graft thrombectomies were performed in a manner similar to that performed on native arteries. Our practice was to approach a failed infrainguinal PTFE bypass graft at its distal anastomosis, which allowed an evaluation of the outflow system and identification and correction of the most common site for intimal hyperplasia. The earlier distal incision was opened, and the distal end of the graft, the distal anastomosis, and the proximal and distal native artery were dissected free. A longitudinal incision was then made in the distal end of the graft within a few millimeters of its distal tip. An initial extraction with Fogarty balloon embolectomy catheters was accomplished with extraction of soft clots. This was followed by Fogarty adherent clot catheters or graft thrombectomy catheters, as needed, to remove the adherent thrombus that was frequently encountered in artificial conduits. Completion retrograde angiography (with an 18-gauge single-wall needle, a 0.035-in guidewire, and a 5F catheter) was performed as a means of delineating the integrity of the graft and assessing the proximal and distal suture lines and runoff vessels. Stenosis at the suture line or just distal to it was corrected by extending the graft incision distally across its apex and into the recipient artery until its lumen was no longer narrowed. An autogenous vein patch was then inserted across the stenosis to widen the lumen.
In three patients who elected to undergo lysis/PTA, the grafts could not be catheterized (failed lysis). Therefore, after operative thrombectomy (via the common femoral artery), intraoperative balloon angioplasty was performed with balloon catheters (Boston Scientific, Watertown, Mass) in 2-to 4-cm lengths and 5-to 8-mm in diameter, according to the length of the lesion and the size of the artery as measured by means of intraoperative arteriograms. The balloons were dilated to 8 to 15 atmospheric pressure for 1 to 2 minutes. After balloon angioplasty, pressure gradients, proximal and distal to the lesions, were measured to assess hemodynamic success. The pressure gradient was determined by measuring the proximal femoral artery pressure and the popliteal pressure distal to the lesion. Completion angiography was also performed. These three patients were kept in group B because the emphasis of the follow-up data was on the methods by which the underlying cause of failure was treated (ie, open patch repair vs PTA).
Early success was achieved when there was no residual stenosis, as defined radiologically (<30% luminal narrowing) and hemodynamically when the pressure gradient was abolished or decreased to less than 10 mm Hg. The same principle was applied to patients treated with open repair or lysis/PTA.
Heparin (5000 units) was given intravenously before the thrombectomy, and in all patients, anticoagulation with warfarin was maintained at an international normal-JOURNAL OF VASCULAR SURGERY Volume 35, Number 2
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ized ratio of 2 to 3 indefinitely. Antiplatelet therapy (325 mg aspirin daily) was also started within 24 hours after surgery.
Thrombolysis/percutaneous transluminal balloon angioplasty. The initial diagnostic arteriogram was performed through the contralateral femoral artery by using 5F catheters. The femoropopliteal grafts were cannulated by means of either the crossover technique (contralateral approach) or the ipsilateral femoral artery approach. All patients, except the last three, received intra-arterial catheter-directed thrombolysis with urokinase (250,000 units bolus followed by 4000 units/min for 4 hours, then 2000 units/min for as long as 60 hours). The last three patients were given intra-arterial catheter-directed thrombolysis with recombinant tissue plasminogen activator (rt-PA), 0.05 to 0.1 mg/kg/h for as long as 12 hours. The rt-PA dosage used in our study was similar to that used in earlier studies. 11 Multi-side hole catheters were used for lysis. All patients also received heparin (5000 units intravenously, followed by 1000 units/h) to maintain an activated partial thromboplastin time of 1.5 to 2 times the control. We continued to give heparin until optimal postthrombolytic management was achieved. The progression of lysis was monitored by using color duplex ultrasound scanning (every 6-12 hours) and angiography every 12 hours until lysis was complete (luminal continuity with <10% residual clot). Systemic fibrinolytic effects were monitored by measuring the prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen level, and fibrinogen degradation products. The activated partial thromboplastin time and the prothrombin time were maintained at 1.5 to 2 times the control, and the fibrinogen level was maintained at more than 100 mg/dL. The infusion of lytic agents was halted when the fibrinogen level fell below 100 mg/dL for a few hours before resuming the infusion.
PTA was performed as aforementioned for any underlying graft suture anastomotic lesions. Proximal lesion PTAs were performed via contralateral femoral artery cannulation, and distal lesion PTAs were performed via ipsilateral femoral artery cannulation or by means of the contralateral approach.
After successful lysis, anticoagulation with heparin was undertaken in all patients, followed by the administration of warfarin indefinitely, maintaining an international normalized ratio of 2 to 3 times the control. Patients were also given 325 mg of aspirin daily within 24 hours postoperatively.
Intraoperative and postoperative surveillance. Follow-up consisted of clinical examinations supplemented with duplex scanning examinations and ankle brachial index measurements at 1, 3, 6, and 12 months and every 12 months thereafter. Every effort was made to comply with the reporting standards for lower-extremity endovascular procedures advocated by the Ad Hoc Committee of the Joint Council of the SVS/ISCVS. [23] [24] [25] Perioperative morbidity and mortality were defined as events occurring within 30 days postoperatively. Graft patency was assessed by means of duplex scanning examination, and the clinical/hemodynamic improvements were judged by means of the clinical examination and the ankle brachial indices. Arteriograms were obtained when new symptoms developed, a 15% drop in the ankle brachial index was detected, or more than 50% stenosis or occlusion of the graft was documented by means of a duplex scanning examination.
Statistical analysis. The demographic and clinical characteristics of both groups were assessed by using the Pearson chi-square and Fisher exact tests, with a P value less than .05 considered to be significant. The cumulative primary and secondary patency rates for both groups were compared by using the Kaplan-Meier life table analysis. The cumulative success rates for both groups were then compared by using the log-rank test and confirmed with the Wilcoxon test. The method used to calculate the SE (Tables IV and V) is based on the Kaplan-Meier productlimit life table survival analysis.
RESULTS
The indications for intervention in group A (open repair) included 16 patients (52%) with SVS/ISCVS category I acute ischemia and 15 patients (48%) with category II acute ischemia. The indications for intervention in group B included 16 patients (62%) with category I acute ischemia and 10 patients (38%) with category II acute ischemia. The mean duration of ischemia for groups A and B were similar (3.1 and 3.3 days, respectively; range, 0-14 days). The mean follow-up period was 54.1 days (SE, 2.2 months) and 46.2 months (SE, 3.2 months) for group A and group B, respectively. The mean age of the grafts from original insertion to occlusion was 14.3 months for group A (range, 6-38 months) and 13.5 months for group B (range, 4-41 months). No patients were lost to follow-up. Table I summarizes the demographic and clinical characteristics of both groups. The runoff below the distal anastomosis was comparable in both groups (ie, no significant mid-distal popliteal artery disease with 2-3 belowknee vessel runoff). There were no statistically significant differences between the groups. The grafts could not be catheterized (failed lysis) in three patients who elected to undergo lysis/PTA; therefore, they underwent operative thrombectomy and balloon angioplasty and were included in group B. Antegrade flow through the graft was reestablished after a mean of 11 hours of lytic infusion (range, 6-18 hours). However, a complete clot lysis (obtained in all patients) with visualization of the distal runoff necessitated 12 to 60 hours of lytic infusion (mean, 26 hours).
At 30 days, 29 of 31 patients (94%) in group A had improvement in their clinical outcome, as defined by means of improvement by at least one clinical category, 20 versus 24 of 26 patients (92%) in group B (statistically nonsignificant). In these four patients with failed clinical improvement, the time between the onset of thrombosis and intervention was 12 days in one patient, 13 days in one patient, and 14 days in two patients. Table II summarizes the perioperative complications for both groups, with no statistically significant differences. Two patients in the lysis/PTA group had significant dissection at the distal suture line (the site of the PTA), and both were treated with stenting. Two other patients had anastomotic disruptions, and both underwent open repair of the disruption. These two patients remained in the lysis/PTA group for follow-up. Table III summarizes the early and late graft patency and limb salvage rates. The initial technical success and the 30-day graft patency rates were comparable for both groups. One graft from each group thrombosed early, and both were treated successfully, one with thrombectomy and one with lysis. Overall, 17 of 31 patients (55%) in group A had open grafts with no further interventions versus six of 26 patients (23%) in group B (P = .012). Nine of 31 grafts (29%) in group A failed versus 15 of 26 grafts (58%) in group B (P = .027). Of the nine failed grafts in group A, six were treated by inserting new bypass grafts with autogenous saphenous veins, and three were treated conservatively. Of the 15 failed grafts in group B, 11 were treated by inserting new grafts with autogenous saphenous veins, and four were treated conservatively. The limb-loss rate was comparable in both groups (6% vs 12%). Two patients lost limbs in group A, one at 46 months and one at 59 months, versus three patients in group B, one at 23 months, one at 34 months, and one at 60 months.
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Thirty-five further interventions were needed to maintain patency in group B (mean, 1.35; range, 0-3) versus five in group A (mean, 0.16; range, 0-1; P < .05). Table IV and Fig 1 illustrate a comparison of the cumulative primary patency rates, beginning after the use of each of these two alternative methods and ending at the time of the next graft failure, excluding further intervention in both groups. The cumulative primary patency rates at 6 months and 1, 2, 3, 4, and 5 years were 97%, 94%, 87%, 83%, 71%, and 58%, respectively, for group A and 92%, 42%, 26%, 26%, 22%, and 22%, respectively, for group B (P = .0005). The overall cumulative secondary patency rates at 6 months and 1, 2, 3, 4, and 5 years were 100%, 93%, 85%, 72%, 67%, and 62%, respectively, for group A and 100%, 96%, 88%, 76%, 63%, and 45%, respectively, for group B (P = .035; Table V, Fig 2) .
DISCUSSION
Several authorities advocate the preferential use of PTFE grafts in certain patients for the above-knee locations, claiming early efficacy equal to that of autogenous saphenous vein grafts. [26] [27] [28] [29] [30] [31] Therefore, many of these grafts are presently inserted in above-knee femoropopliteal bypass grafts.
There have been many attempts in the last 10 to 15 years at identifying the most appropriate method for treating failed or failing bypass grafts. [3] [4] [5] 8, 9, 11, 14 Options have included surgical thrombectomy with or without revision, When the decision is made to salvage an old PTFE graft, which may be appropriate if the original location is above the knee, the proper surgical techniques are critical in obtaining a good outcome. Surgical thrombectomy of these grafts is generally performed by approaching the graft at the distal anastomosis, which allows evaluation of the outflow system and identification and correction of the most common site for intimal hyperplasia. The earlier distal incision is opened, and the distal anastomosis and the proximal and distal arteries are dissected free. The graft is then opened with a longitudinal incision to within a few millimeters of its distal tip. The graft is then thrombectomized by using balloon catheters that are passed proximally and distally. This is followed by completion angiography as a means of evaluating graft patency and the status of the anastomotic sites and the runoff. When intimal hyperplasia is noted at or just distal to the anastomosis, the opening in the graft is extended across its apex and into the popliteal artery to a point beyond the disease. Saphenous vein patch angioplasty is used as a means of closing this opening, and completion angiography is performed. When a lesion is limited to the first 1 to 2 cm of the distal anastomosis, a saphenous vein patch angioplasty to include the distal portion of the graft is a reasonable option. Acceptable incremental 3-year patency rates have been reported for this strategy of graft salvage for failed femoropopliteal above-knee PTFE grafts. 19, 21 Other options may be used, including performance of a new autogenous saphenous vein bypass grafting procedure, particularly for below-knee locations.
Alternative therapy includes catheter-directed thrombolytic therapy to lyse the clot and reveal the cause of graft failure, which can be corrected by means of an operative or endovascular procedure.
Intra-arterial catheter-guided thrombolytic therapy gives excellent immediate results, with recanalization in more than 70% of recently thrombosed grafts. [10] [11] [12] 15, 16, 32, 33 Despite these initial good results, durability is short-lived. 10, 12, 15, 17, [34] [35] [36] [37] Several studies have reported that as many as 50% of successfully recanalized grafts reocclude within the first year. 10, 12, 15, 17, [34] [35] [36] [37] [38] [39] Berkowitz 12 reported a 72% initial success rate, which decreased to 23% at 5 years. In this series, even after correcting the underlying causative anatomic defect, and despite indefinite anticoagulation and antiplatelet therapy, the 5-year patency rate in the lysis/PTA group was 45%. In a review of catheter-directed thrombolysis for arterial and bypass graft occlusion, Durham and Rutherford 38 reported that 50% of successfully opened grafts re-occluded within 6 months.
Two major prospective randomized trials of thrombolytic therapy for lower-extremity ischemia have been reported. 18, 40 The results of these two trials were consistent with that of other reports, 11 and they confirmed that patients with acute ischemia of the lower extremity caused by thrombotic occlusion of either grafts or native arteries could be treated effectively with preoperative percutaneous lytic therapy. In the STILE trial, lytic therapy was a successful means of restoring patency in 69% of native arteries and 81% of the bypass grafts when the lytic agent was delivered into the clot. There was a reduction in the extent of planned surgical intervention in 56%. After 6 months' follow-up, there were fewer amputations in those patients with acute ischemia randomized to lysis than in patients undergoing initial surgery (6% vs 18%; P = .061).
One of the major limitations of lysis was the inability to place a catheter into the clot, which was noted in 41% of patients with occluded grafts. In the thrombolysis or peripheral arterial surgery (TOPAS) trial, recanalization was achieved in 80% of patients, and complete lysis was obtained in 68% of patients. The amputation-free survival rate after 6 months' follow-up was similar in both groups (72% vs 75%). Thirty-two percent of patients who were treated successfully with lytic therapy had underlying lesions that were treated percutaneously, avoiding surgery. At 1 year, there was a 65% rate of amputation-free survival in patients undergoing successful lytic therapy, as compared with the 70% rate for patients who underwent surgery. Thrombolytic therapy can unmask flow-limiting lesions that may be the cause of graft thrombosis. Correction of the underlying flow-limiting lesion is essential in maintaining long-term graft patency. 10, 15, 18, 36, 41 However, balloon angioplasty of anastomotic fibrous intimal hyperplasia is characterized by a high recurrence rate, reported to range from 51% to 78% at 3 years. 10, 14, 36, 42 This is probably related to the limited compressibility of the hyperplastic lesions. 10 Bull et al 10 reported that surgical correction, even when it is technically more challenging, gives more durable results than percutaneous angioplasty (1-year patency, 60% vs 31%, respectively). Similar observations were noted in our experience. Our 5-year cumulative primary patency rate was 58% for open repair versus 22% for PTA, and most of the stenotic lesions that underwent PTA needed further revision to maintain patency. The patency rate of these grafts might have been worse in both groups if warfarin sodium had not been used. Similar findings were noted by Sanchez et al, 5 who reported patency rates of 56% for lysis/PTA and 71% for surgery (40% of their grafts were PTFE). Our patency rates were equivalent in the two groups after as long as 4 years of follow-up. This may suggest that the late differences are caused by disparate durability of patch angioplasty versus balloon angioplasty of the anastomotic lesion, rather than the method of initial thrombus extraction. However, the low patency rate of these grafts after balloon angioplasty of these grafts was not associated with unfavorable limb salvage. Several studies reported that almost two-thirds of the re-thrombosed grafts were hemodynamically well tolerated and not limb threatening. 10, 12, 16, 18, 36, 37 The findings of our study reveal that thrombectomy with open surgical repair is superior to thrombolysis and PTA for the treatment of failed above-knee PTFE femoropopliteal bypass grafts. Similar findings, although in a slightly different but comparable population, were obtained in the STILE study. 18 The authors of that study concluded that surgical revascularization was significantly better than thrombolysis in the primary treatment of lower-extremity bypass grafts. Balloon angioplasty may continue to have a role in the treatment of patients with medical contraindications to surgical intervention.
